Literature DB >> 285734

Interrelationship of immunologic characteristics, proliferation pattern, and prednisone sensitivity in acute lymphoblastic leukemia of childhood.

J A Bakkeren, G A de Vaan, H F Hillen.   

Abstract

In children with acute lymphoblastic leukemia (ALL) the effect of prednisone therapy on the cell-cycle phase distribution of leukemic bone marrow cells was determined with pulse cytophotometry at the time of diagnosis. Also, the interrelationship with the presence of the sheep erythrocyte receptor as a marker for T cells was investigated. In 17 or 21 patients prednisone treatment caused a decrease in the percentage of cells in the S+G2+M phases. In 11 of 12 adult patients with ALL the same result was obtained. In a group of 31 children with ALL, 6 cases of T-cell ALL occurred in combination with intermediate or high WBC counts. The 3 patients with the highest E-rosetting percentages had rather high proportions of bone marrow cells in the S+G2+M phases. No correlation could be established between the WBC count or the E-rosetting percentage and the chance for complete remission.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 285734

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Morphology and incidence of the "posttherapeutic lymphoid cell" in the bone marrow of children with acute lymphoblastic leukemia.

Authors:  J H Schuurmans Stekhoven; C A Langenhuysen; J A Bakkeren; R Holland; I Höller; G A De Vaan; E D Schretlen
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

2.  Antibody deficiency and isolated growth hormone deficiency in a girl with Mulibrey nanism.

Authors:  A Haraldsson; C J van der Burgt; C M Weemaes; B Otten; J A Bakkeren; G B Stoelinga
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

3.  Griscelli disease with cerebral involvement.

Authors:  A Haraldsson; C M Weemaes; J A Bakkeren; R Happle
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.